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SUMMARY
We have developed a nonheuristic genome topography scan (GTS) algorithm to characterize the patterns of
genomic alterations in human glioblastoma (GBM), identifying frequent p18INK4C and p16INK4A codeletion.
Functional reconstitution of p18INK4C in GBM cells null for both p16INK4A and p18INK4C resulted in impaired
cell-cycle progression and tumorigenic potential. Conversely, RNAi-mediated depletion of p18INK4C in
p16INK4A-deficient primary astrocytes or established GBM cells enhanced tumorigenicity in vitro and
in vivo. Furthermore, acute suppression of p16INK4A in primary astrocytes induced a concomitant increase
in p18INK4C. Together, these findings uncover a feedback regulatory circuit in the astrocytic lineage and
demonstrate a bona fide tumor suppressor role for p18INK4C in humanGBMwherein it functions cooperatively
with other INK4 family members to constrain inappropriate proliferation.
Open access under CC BY license.INTRODUCTION
GBM, the most common primary brain tumor in adults, is neuro-
logically destructive and maintains dismal responses to virtually
all therapeutic modalities. The pathobiology of GBM is charac-terized by rapid proliferation as well as widespread invasion,
robust angiogenesis, apoptosis resistance, and florid necrosis
(Furnari et al., 2007). On the molecular level, GBM is character-
ized by coactivation of receptor tyrosine kinases (Huang et al.,
2007; Stommel et al., 2007), activation of PI3K-AKT signalingSIGNIFICANCE
Understanding the molecular basis of human cancer and, thereby, targeting the genetic defects in a rational manner re-
quires a comprehensive knowledge of not only the driving pathogenetic lesions but also their interactions. Using a newly
developed algorithm that enables the analysis of copy number profiles based on focality, amplitude, and recurrence of
the genomic events, we uncovered a codeletion pattern among closely related INK genes in the GBM oncogenome, chal-
lenging the prevailing single-hit model of RB pathway inactivation. Elucidation of the molecular basis underlying this code-
letion pattern revealed a backup tumor suppressor role for p18INK4C in the setting of p16INK4A deletion, thus expanding our
understanding of human GBM and compensation among INK family members in human tumors.Cancer Cell 13, 355–364, April 2008 ª2008 Elsevier Inc. 355
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tumor suppressor pathway function (Furnari et al., 2007).
Disruption of the RB pathway appears to be an obligate event
in tumorigenesis and is achieved primarily through either dele-
tion/mutation of RB, amplification of the G1 cyclin-dependent
kinases 4 or 6 (CDK4/6), or deletion/silencing of the G1 CDK in-
hibitor (CKI), CDKN2A (p16INK4A). In individual human tumor
specimens, these principal components of the pathway—RB-
CDK4/6-p16INK4A—are reported to be targeted in a mutually
exclusive manner (Sherr and McCormick, 2002) consistent with
their overlapping functions in regulating the G1-S transition of
the cell cycle (Massague, 2004). However, recent data in the
mouse have challenged this notion of exclusivity. Sharpless
and colleagues reported that combined germline nullizygosity
for p16Ink4a and its related family member p18Ink4c facilitated
the development of pituitary tumors in the mouse (Ramsey
et al., 2007). Berns and colleagues showed enhanced tumorige-
nicity and expanded tumor spectrum in mice null for p15Ink4b and
p16Ink4a/Arf, compared to p16Ink4a/Arf alone (Krimpenfort et al.,
2007). While these genetic data in the mouse have suggested
cooperation and/or compensation among members of the Ink4
family of CKI, the relevance to human cancers of these findings
in the mouse has not been established.
The recalcitrant nature of GBM and emerging evidence for
genes and genomic loci governing response to both targeted
and conventional therapy (Cahill et al., 2007; Hunter et al.,
2003; Mellinghoff et al., 2005) have motivated efforts to more fully
define the genetics of GBM. Previous conventional and array-
based comparative genomic hybridization (array-CGH) profiles
have revealed numerous recurrent regional copy number aberra-
tions (CNAs) in GBM (Kotliarov et al., 2006; Nigro et al., 2005;
Ichimura et al., 2006; Korshunov et al., 2006; Lee et al., 2006;
Liu et al., 2006; Mulholland et al., 2006; Rossi et al., 2005). The
large numbers of CNAs detected by array-CGH and the resulting
long lists of resident genes have highlighted the need for a sys-
tematic objective prioritization approach designed to separate
true CNA target genes from bystanders.
Here, we report the development of a nonheuristic genome
topography scan (GTS) algorithm to define and rank genomic
regions exhibiting significant CNAs based on genome-wide
array-CGH profiles of primary GBM samples and cell lines. In
addition to the expected GBM signature alterations, GTS identi-
fied many CNAs not previously implicated in GBM development,
uncovered genomic codeletion of two highly related G1 CKIs,
p18INK4C and p16INK4A, in human GBM tumors and cell lines,
leading to discovery and validation of a previously unappreciated
cell-cycle regulatory circuit in the astrocytic lineage.
RESULTS
GTS Defines Regions of Interest Encompassing
Focal and Recurrent CNAs
To identify novel GBM-relevant genes, we performed high-
resolution, oligo-based array-CGH profiling to determine the
genome-wide CNA patterns of 28 pathologically verified primary
Grade IV glioma (GBM) specimens and 18 established glioma
cell lines (Table S1 available online). Using a rule-based algo-
rithm to define minimal common regions (MCRs) of CNAs based
on amplitude, width, and recurrence of CNAs (Aguirre et al.,356 Cancer Cell 13, 355–364, April 2008 ª2008 Elsevier Inc.2004; Carrasco et al., 2006; Tonon et al., 2005), we readily
identified the signature genomic events known previously for
GBM (e.g., EGFR amplification or CDKN2A deletion) as well as
many previously uncharacterized alterations (Table S2). In view
of the large number of CNAs and the complexity of overlap
across samples, we developed a nonheuristic methodology,
genome topography scanning (GTS), to more rigorously define
and rank genomic regions based on the amplitude, width, and
recurrence of a CNA.
In two dimensions, array-CGH measures the relative changes
in chromosomal copy number as a deviation from the baseline
diploid state at every interrogated position along the genome.
As such, it captures both the amplitude and width of a CNA in
a tumor. Since the frequency of a CNA is believed to be a strong
indicator of potential biological significance, recurrence is
considered the third dimension for defining the topography of
a CNA in GTS. We derived two indices to capture these three
major features describing the topography of any given CNA.
First, the Aberration amplitude and Recurrence Index (ARI)
measures the composite contribution of the copy number value
(log2 amplitude of the CNA) and the frequency of the aberration
(recurrence) at a genomic position (See Experimental Proce-
dures). Second, the Aberration Focality Index (AFI) weights the
amplitude and recurrence inversely by an estimate of the number
of genetic elements spanned by the CNA (see Experimental
Procedures). Thus, the AFI assigns to each region in the genome
a measure of the likelihood of any genetic element within the
region representing the true target of genomic alterations across
a sample set. With ARI and AFI calculated for each genomic
position, we represented the GBM oncogenome in a typical
skyline profile, with ARI on the vertical axis and AFI on the
color-scale (Figure 1A). Not surprisingly, salient events in red
(high AFI) with high amplitude and recurrence (high ARI) coincide
with known common, high-amplitude and focal CNAs in GBM,
including EGFR, PDGFRA, MET, PTEN, and CDKN2A/B
(p16INK4A/p15INK4B).
Next, we generated two-dimensional GTS plots with each dot
representing a region of interest (ROI) defined by peaks in the ARI
and AFI (Figure 1B, see Experimental Procedures). Since high
ARI and AFI represent focal events with high amplitude and
recurrence, the well-known signature events in GBM were
grouped in the upper right as expected (Figure 1B, red circles).
The importance of focality in identifying candidate targets is
highlighted by separation of ROIs spanningMET or PTEN, driven
by their high AFI, from the background of regional but highly
recurrent Chr7 gain or Chr10 loss, respectively (Figure 1B,
clusters of blue dots correspond to Chr7 and Chr10 ROIs,
respectively). Moreover, infrequent but focal CNAs could
be identified on the GTS plots based on their high AFI score
(y axis) despite low ARI (x axis), as were the cases of infrequent
but focal deletion of APAF1 and FBXW7, not previously
described in GBM (Figure 1B, green circles).
To rank the likely significance of GTS-defined ROIs, we calcu-
lated a GTS score reflecting the combined contributions of ARI
and AFI for each ROI and listed the top 50 rank-ordered amplifi-
cations and deletions, respectively, in Table 1. Additionally, since
copy number aberration is a known mechanism to dysregulate
expression, we generated RNA transcriptome profiles on a sub-
set of samples to identify those ROI-resident genes whose
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INK4 Feedback Circuit in Glioblastomaexpression patterns were concordant with their copy number.
Here, we calculated a gene’s gene weight (GW) (Aguirre et al.,
2004) (see Experimental Procedures) and considered those
with p values less than 0.05 as exhibiting copy-number-concor-
dant expression (Table 1, in blue). By such GW criteria, 30% of
ROI-resident genes (26/80 in amplified ROIs; 16/58 in deleted
ROIs) showed copy-number-concordant expression, including
all of the known signature events. Interestingly, among those
not exhibiting such concordance are FBXW7 and APAF1, point-
ing to additional common mechanisms for their inactivation in
GBM (see Discussion).
Codeletion of CDKN2C and CDKN2A via a Feedback
Regulatory Circuit in Human GBM
The CDKN2C (p18INK4C) locus was identified by GTS as the top
deletion peak in our data set (Table 1). Focused analysis of the
array-CGH profiles (Figure 1C) revealed a clearly defined 436
kb minimal common region delimited by a homozygous deletion
of the p18INK4C locus in a GBM cell line (solid lines), with slightly
larger regions defined by CNAs detected in two primary GBM
specimens (dashed lines). That p18INK4C is the target of these
Figure 1. Analyses of GBM Oncogenome by GTS Identi-
fied CDKN2C Deletion
(A) Skyline profile of GBM oncogenome with ARI on y axis. AFI is
represented by color scale based on percentile rank, highlighting
the most focally altered regions.
(B) Two-dimensional GTS plots of log(ARI) (x axis) and log(AFI)
(y axis) for amplification (left) and deletion (right). Black outer circles
mark ROIs ranked among top 50 by GTS scores (Table 1). Red
circles mark ROIs spanning signature events. ROIs on frequently
gained chr7 are marked in blue on the amplification plot. Similarly,
ROIs on chr10 are marked in blue on the deletion plot. Note sep-
aration of MET or PTEN from Chr7 or Chr10 events, respectively.
(C) Deletion ROI spanning CDKN2C is present in 4/28 glioblas-
toma tumor samples (two examples shown), defining a focal
minimal common region of deletion of 2Mbp (dashed lines).
Homozygous deletions are common in glioma cell lines (5/18)
and further refine the minimal common region of deletion to
p18INK4C (solid lines). Analysis of copy-number-concordant
expression by gene weight modeling (see Experimental Proce-
dures) demonstrates highly significant coordinate loss of
p18INK4C expression in tumors and cell lines that show chromo-
somal deletion. Gene weights for both probe sets for p18INK4C
are significant at p < 0.01 (black circles). GW Sig, gene weight
significance.
deletions was supported by finding that all 9 samples
with this CNA showed reduction or loss of p18INK4C
RNA expression (Figure S1), and gene weight model-
ing confirmed copy-number-concordant expression
pattern for both p18INK4C probes (Figure 1C).
The observation of genomic deletion of p18INK4C
was, at first glance, counterintuitive since all samples
sustaining the p18INK4C deletion (n = 9 of 46;
p = 0.009, Fisher’s exact test) also harbored concur-
rent deletion of the CDKN2A/CDKN2B locus encom-
passing its related family members, p16INK4A and
p15INK4B. Survey of a panel of 747 human cancer cell
lines of 32 anatomical origins for genomic status of
CDKN2A (p16INK4A and p14ARF) and CDKN2C revealed that co-
deletion of these two loci was observed predominantly in glioma
tumor cell lines (Table S3). Although protein expression by immu-
nohistochemistry (IHC) does not inform the mechanism of non-
expression (e.g., pathological inactivation by genomic deletion
versus normal physiological regulation), IHC analyses of
p16INK4A and p18INK4C expressions on GBM tissue microarrays
containing an independent set of GBM tumor specimens con-
firmed that a proportion of human GBM tumors (n = 10 of 59 in-
formative cores) expressed low to undetectable levels of both
proteins (Figure S2 and Table S4). Additionally, resequencing
of p18INK4C in 53 human glioma cell lines (Table S5) identified
three sequence variants of p18INK4C in p16INK4A-deleted cell
lines. While we cannot definitively rule out the possibility that
these represent rare germline variants without corresponding
germline normal DNA, two of these three nonsynonymous se-
quence variants, p.F37I in GB-1 and p.A61D in KNS-60, targeted
highly conserved or invariant amino acid residues (Figure S3).
Several lines of evidence suggest that the known principal RB
pathway lesions in human tumors act in a mutual exclusive man-
ner (Sherr and McCormick, 2002). However, in the mouse, it has
been shown that loss of p18Ink4c and p16Ink4a can cooperate toCancer Cell 13, 355–364, April 2008 ª2008 Elsevier Inc. 357
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List of top 50 amplified (left) and deleted (right) ROIs, respectively, rank-ordered by GTS scores. ROI resident genes with gene-weight significance
(p < 0.05) are highlighted in blue. Italics mark genes not represented on the expression array. Known GBM signature genes are in bold.induce pituitary tumor formation (Ramsey et al., 2007), suggest-
ing that p18Ink4c may have independent tumor suppressive activ-
ity in a pathway parallel to that of its related family member
p16Ink4a. Along the same line, mice null for both p15Ink4b and
p16Ink4a/Arf exhibited a broader tumor spectrum than mice
deficient for p16Ink4a/Arf alone (Krimpenfort et al., 2007). On the
other hand, the presence of an E2F binding site within the
p18INK4C promoter (Blais et al., 2002) raised the possibility of
a regulatory loop, where inactivation of p16INK4A in nascent
cancer cells triggers a compensatory upregulation of p18INK4C
via E2F, leading to genetic pressure for its concomitant or
subsequent deletion.
To explore this hypothesis of a feedback circuit involving
p18INK4C via E2F1, we performed chromatin immunoprecipita-
tion and found that, in proliferating human astrocytes, the
activating E2F1 transcription factor was indeed bound physically
to the p18INK4C promoter (Figure 2A). Moreover, transient
enforced expression of E2F1 in primary human astrocytes led358 Cancer Cell 13, 355–364, April 2008 ª2008 Elsevier Inc.to a specific increase in p18INK4C RNA, but not the other three
related INK4 CKIs (Figure 2B). Acute suppression of p16Ink4a in
immortalized (p53/) murine astrocytes resulted in a significant
induction of p18Ink4c protein (Figure 2C). Quantitative real-time
RT-qPCR demonstrated that this is at least in part due to regula-
tion of transcription or message stability because suppression of
p16Ink4a by siRNA (siInk4a) resulted in a 2-fold increase of
p18Ink4c RNA compared to control cells transfected with nontar-
geting siRNA (siNT) (Figure 2D), an effect that was maintained for
up to 120 hr posttransfection (data not shown). Similarly,
RT-qPCR analysis of normal human astrocytes showed a 3.5-
fold increase in p18INK4C expression following p16INK4A knock-
down (Figure 2D). A modest upregulation of p15INK4B was also
observed while p19INK4D was not induced upon p16INK4A knock-
down. Taken together, these data supported the view that
a p16INK4A-E2F1-p18INK4C feedback circuit is operative in the
astrocytic lineage and underlies pressure for codeletion of these
two related CKIs in GBM tumors.
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Compensatory Upregulation of p18INK4C
(A) E2F transcription factors bind the p18INK4C promoter in
human astrocytes. A p18INK4C promoter DNA fragment
was immunoprecipitated with anti-E2F1, but not with the
control or an RB1 antibody. (B) Human astrocytes were
transiently transfected with empty vector or expression
constructs for E2F1 and E2F5. INK4 and CCNE1 RNA ex-
pression was analyzed by RT-qPCR at 72 hr after transfec-
tion and normalized to GAPDH expression. Vector trans-
fected cells were set to 1 for each transcript. E2F1, but
not E2F5, specifically increased p18INK4C (INK4C) RNA
to a similar extent as the well-characterized E2F target
CCNE1. Error bars represent mean ± standard deviation.
(C) Astrocytes from p53/ mice at passage 2 were trans-
fected with nontargeting siRNA (siNT) or siRNA targeting
p16Ink4a (siInk4a) and assayed for p18Ink4c protein expres-
sion at 72 hr after transfection. Loading control, vinculin.
(D) Murine p53/ astrocytes and normal primary human
astrocytes were transfected with siNT or siInk4a and
assayed for RNA expression levels of p16Ink4a (Ink4a),
p15Ink4b (Ink4b), p18Ink4c (Ink4c), and p19Ink4d (Ink4d) by
RT-qPCR at 72 hr posttransfection. Relative levels com-
pared to Ink4 expression of siNT-transfected cells are
shown after normalization to Gapdh. Error bars represent
mean ± standard deviation.Functional Significance of p18INK4C Inactivation
in p16INK4A-Deleted GBM Cells
To assess the functional significance of such a transcriptional
feedback circuit, we asked whether p18INK4C inactivation would
further enhance the malignant properties of GBM beyond those
conferred by p16INK4A loss (Table 2). Here, we made use of two
established GBM cells, LN-18 and Hs683, which retain p18INK4C
but lack p16INK4A. Using two shRNA constructs capable of
knocking down p18INK4C RNA by 45%–53% (Figure 3A),
p18INK4C depletion caused a 1.5- to 3.5-fold increase in anchor-
age-independent colonies in LN-18 and Hs683, respectively
(Figure 3A). These p18INK4C shRNAs had no effect on soft-agar
formation in p18INK4C-null LN-229 cells or in Cyclin D1/CDK4-
amplified LN-Z308 cells, indicating that the phenotypes are not
due to nonspecific shRNA effects. Similar results were obtained
using synthetic p18INK4C siRNA oligos, where in the p16INK4A null
and p18INK4C-WT cell lines LN-18 and LN-444, 50% knockdown
of p18INK4C increased soft agar colony formation 2- and 8-fold,
respectively (Figure S4). Again, p18INK4C knockdown did not
increase colony formation in LN-Z308 cells (Table 2). Conversely,
Table 2. Summary of p18INK4C Gain-of-Function and
Loss-of-Function Studies
Tumorigenicity (Soft Agar
Growth)
CDKN2A p18INK4C
CCND1/
CDK4
p18INK4C
Expression
p18INK4C
KD
LN-18 null WT WT decrease increase
LN-444 null WT WT decrease increase
Hs683 null WT WT N/A increase
LN-229 null null WT decrease no change
U87MG null null WT decrease N/A
LN-Z308 WT WT amp no change no changewe examined the consequences of p16INK4A and p18INK4C
reconstitution in U87MG and LN-229, two established GBM cells
with concomitant deletions of the p16INK4A and p18INK4C loci as
documented by copy number profiling and/or qPCR (data not
shown). As expected, comparable levels of enforced expression
of p16INK4A and p18INK4C in U87MG cells (Figure S5A) signifi-
cantly inhibited proliferation (Figures S5B and S5C) and anchor-
age-independent growth in vitro (Figure 3B; Table 2). In contrast,
enforced expression of p16INK4A or p18INK4C had no impact in
LN-Z308 GBM cells with amplification and overexpression of
Cyclin D1 and CDK4 and intact p16INK4A and p18INK4C genomic
loci) (Table 2; Figure 3B; Figure S5C).
That the combined loss of p16INK4A and p18INK4C function
confers enhanced malignant potential over that associated
with p16INK4A loss alone in human GBM cells was further sub-
stantiated by demonstration that tumor-associated p18INK4C
variants occurring at highly conserved residues (p.F37I in GB-1
and p.A61D in KNS-60; Figure S3) were loss-of-function
mutants. Specifically, reconstitution of these variants in
p18INK4C null cell lines imparted at best 50% of suppressive
activity of wild-type p18INK4C in both anchorage-independent
growth and cell proliferation assays (Figure 3C; Figure S6; data
not shown). Mechanistically, we found that the F37I and A61D
variants did not bind CDK6 in coimmunoprecipitation studies
(Figure 3D), thus providing a molecular basis for the loss-
of-function phenotype of these mutant alleles.
Inactivation of p18Ink4c in p16Ink4a-Deficient Primary
Astrocytes Conferred Tumorigenicity
The molecular evidence of compensatory regulation between
p16Ink4a and p18Ink4c in astrocytes suggested that complete
deactivation of RB pathway tumor suppression activities in this
cell type will require concomitant inactivation of both CKIs. To
directly address this point, we compared in vivo tumorigenic
potential of primary astrocytes that were inactivated forCancer Cell 13, 355–364, April 2008 ª2008 Elsevier Inc. 359
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GBM Cell Lines Enhances Tumorigenicity
(A) GBM cells, LN-229 (p16INK4A/p18INK4C null), LN-18,
Hs683 (both p16INK4A null, p18INK4C WT), and LN-Z308
(p16INK4A/p18INK4C WT, CDK4/Cyclin D1-amplified)
infected with retroviral expression constructs for small
hairpins targeting p18INK4C (shINK4C-2 and shINK4C-5)
or a nontargeting hairpin (shNT) were scored for colony
formation in soft agar at day 14 and plotted as percentage
of shNT controls. Error bars represent standard deviation
of duplicates. Suppression of p18INK4C significantly
increased the number of colonies in LN-18 (p = 0.01 and
p = 0.006 for shINK4C-2 and shINK4C-5, respectively)
and Hs683 (p = 0.07 and p = 0.004 for shINK4C-2 and
shINK4C-5, respectively). Degrees of p18INK4C knock-
down were determined by RT-qPCR relative to shNT-
infected cells (100%) and indicated in the bottom table.
Error bars represent mean ± standard deviation.
(B) p16INK4A/p18INK4C null GBM lines U87MG and LN-229
as well as p16INK4A/p18INK4C WT, CDK4/Cyclin D1-ampli-
fied LN-Z308 stably infected with retroviral expression con-
structs for Flag-tagged p16INK4A (INK4AFLAG), Flag-tagged
p18INK4C (INK4CFLAG), WT p18INK4C (INK4C), or empty vec-
tor (Vector) were assayed for colony formation in soft agar.
Soft agar colonies were stained and counted at day 14 and
plotted as percentage ± standard deviation relative to vector-infected cells (U87MG-Vector 100%, U87MG-INK4CFLAG 23 ± 2% [p = 0.0005], U87MG-INK4AFLAG 18
± 2% [p = 0.0003]; LN-229-Vector 100%, LN-229-INK4CFLAG 23 ± 3% [p = 0.0002], LN-229-INK4AFLAG 11 ± 2% [p=0.0001]). The scale bar indicates 2 mm.
(C) GBM cell lines LN-229 (p16INK4A/p18INK4C null), LN-444, LN-18 (both p16INK4A null, p18INK4C WT), and LN-Z308 (p16INK4A/p18INK4C WT, CDK4/Cyclin D1-am-
plified) infected with vector control (Vector), WT p18INK4C (INK4C), or p18INK4C variants (F37I and A61D) were assayed for soft-agar colony formation, as in (B).
Both p18INK4C variants exhibited reduced capability of repressing colony formation. Error bars represent mean ± standard deviation.
(D) Stable LN-229 cell populations were derived as in (C). Wild-type, but not mutant, p18INK4C coimmunoprecipitated with CDK6 (p18INK4C bands are marked by
asterisks). The same effect was observed with binding to CDK4, albeit interaction between wild-type p18INK4C and CDK4 was much weaker (data not shown).p16Ink4a/Arf alone or for p16Ink4a/Arf and p18Ink4c. Here, we used
lentivirally delivered shRNA targeting p18Ink4c in primary
nontransformed p16Ink4a/Arf/ astrocytes to determine whether
inactivation of p18Ink4c bestowed oncogenicity to these nontu-
morigenic primary cells. Reduction of p18Ink4c expression in
already p16Ink4a-deficient primary astrocytes conferred anchor-360 Cancer Cell 13, 355–364, April 2008 ª2008 Elsevier Inc.age-independent growth in vitro and turmorigenicity in vivo (Fig-
ure 4). Specifically, using two independent shRNA (data shown
for one shRNA), near complete and stable knockdown of
p18Ink4c (Figure 4A inset) in primary p16Ink4a/Arf/ astrocytes
resulted in enhanced anchorage-independent growth in semi-
solid medium in culture. When transplanted subcutaneouslyFigure 4. p16Ink4a and p18Ink4c Coinactivation Confers
Tumorigenicity to Murine Astrocytes
(A) Murine p16Ink4a/ARF null astrocytes were infected with
lentiviral shRNA expression constructs targeting GFP (shGFP)
or p18Ink4c (shInk4c). Knockdown of p18Ink4c resulted in dras-
tically lower p18Ink4c protein levels (loading control, vinculin)
and significantly higher colony formation in soft agar (error
bars indicate mean ± standard deviation of quadruples).
(B) Stable astrocyte populations derived as in (A) were subcu-
taneously injected into Ncr nude mice. While p18Ink4c-
deprived cells formed tumors within 2 weeks, control cells
did not generate tumor (mean ± standard deviation plotted).
Injection sites of control mice were histologically confirmed
to be tumor free.
(C) Tumors derived from shInk4c-infected astrocytes dis-
played malignant anaplastic histology and a high mitotic rate
by H&E staining. Immunohistochemical analysis confirmed
expression of the neural marker Nestin in a pattern similar to
human astrocytomas. The scale bar indicates 30 mm.
(D) Matrigel-embedded shGFP-infected astrocytes and
tumor-derived shInk4c-infected astrocytes were assayed for
p18Ink4c RNA expression relative to Gapdh expression
confirming stable p18Ink4c knockdown in tumor cells. Error
bars indicate mean ± standard deviation.
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astrocytes formed malignant tumors that were strongly Nestin-
positive, in contrast to controlled p16Ink4a/Arf/ astrocytes
which were not tumorigenic in vivo (Figures 4B and 4C). The
resultant tumors maintained low to absent p18Ink4c expression
at the RNA and protein levels (Figure 4D and data not shown). En-
hanced in vivo tumorigenic phenotype uponp18Ink4c suppression
was similarly observed in astrocytes deficient for p16Ink4a/Arf
and Pten (Figure S7A). Furthermore, even in the presence of
EGFRvIII oncogene, suppression of p18Ink4c trended toward
development of larger tumors from p16Ink4a/Arf/ astrocytes
(Figure S7B). In conclusion, full transformation of primary
astrocytes in a xenograft model required inactivation of p18Ink4c
in addition to that of p16Ink4a.
DISCUSSION
In this report, we analyzed the copy number and expression
profiles of human GBM cell lines and tumors using a nonheuristic
methodology called GTS. In addition to the well-known and
highly recurrent events, GTS defines and ranks many previously
unrecognized CNAs, uncovers frequent codeletion of two
related CKI genes, CDKN2C and CDKN2A, in human cancers,
and implicates APAF1 and FBXW7 in glioma pathogenesis.
Recent data in the mouse have challenged the dogma of
exclusivity on involvement of major components of the CKI-
CDK4/6-RB cell cycle regulatory axis in cancer. Ramsey et al.
have provided evidence that loss of p18Ink4c can result in upregu-
lation of p16Ink4a in specific murine tissues and that combined
germline nullizygosity for both CKI facilitates the development
of pituitary tumors (Ramsey et al., 2007). Correspondingly,
Krimpenfort et al. have established compensatory p15Ink4b
protein stabilization in p16Ink4a null mice, supporting a coopera-
tive tumor suppressor role for p15INK4B (Krimpenfort et al., 2007).
Whether similar compensatory mechanisms among members of
the Ink4 family of CKI held for humans was uncertain, particularly
given the known cross-species differences in RB pathway regu-
lation in the development of normal and neoplastic cells (Gil and
Peters, 2006; Kim and Sharpless, 2006). Here, the collective
genomic and functional evidence of this report provides the first
documentation of common coinactivation of multiple members
of CKIs in human GBM via genomic codeletion of the
CDKN2A/B and CDKN2C loci or concurrent loss of protein
expression of p18INK4C and p16INK4A.
Importantly, the elucidation of underlying molecular circuitry
driving above patterns of inactivation provides new insight into
RB pathway function in human cancer. By demonstrating
a p16INK4A-E2F-p18INK4C feedback circuit operative in the astro-
cytic cell lineage, we provided molecular basis for ‘‘back-up’’ tu-
mor suppressors such as p18INK4C. We showed that p18INK4C
backup tumor suppressor is engaged in the relatively common
setting of p16INK4A inactivation, resulting in enhanced prolifera-
tion and subsequent E2F-mediated induction of p18INK4C
expression, consequently leading to genetic pressure for subse-
quent inactivation of p18INK4C. It is worth noting that, while its
inactivation is necessitated, at least in part, by its redundant
role with p16INK4A in cell-cycle regulation, our results do not
exclude the possibility that p18INK4C may have additional func-
tional activities beyond G1 CDK inhibition driving its inactivationduring gliomagenesis. On the basis of these data, we conclude
that p18INK4C is a bona fide tumor suppressor in human GBM
and that a hierarchy of tumor suppressive roles for members of
the INK4 CKI exists, wherein p18INK4C likely serves as a back-
up to loss of p16INK4A. Such hierarchy of redundancy speaks
further to the critical importance of intact RB pathway function
in constraining human tumorigenesis.
GTS is a computational methodology for copy number data
that incorporates focality with amplitude in context of frequency
(recurrence) to determine likely significance of a given CNA. The
two scores computed in GTS, ARI and AFI, describe key features
of CNA across samples and provide highly complimentary
information. ARI readily identifies genomic regions which are
recurrently altered while disregarding the focality of CNA events:
common gain of chromosome 7 and recurrent EGFR-region
amplification are both identified as salient alterations in GBM.
AFI scoring further distinguishes genomic regions that are
altered focally versus regionally across samples, measuring the
degree to which CNA is specifically targeting each point in
the genome. Thus, the two scores comprising GTS summarize
the continuum of CNA from wide regional alterations to the highly
focal events, which may directly implicate candidate targets. In
this study, AFI and ARI were given equal weight in delimiting
ROIs, thus preferentially emphasizing high-amplitude focal
aberrations over broader regional alterations; such preference
reflects the fact that the former is more readily amenable to
downstream workup, but not necessarily more important
biologically.
The power of GTS lies in its ability to inform on focal but infre-
quent events that would otherwise be lost in methodologies that
consider mainly amplitude and recurrence. Indeed, infrequent
but focal CNAs can be highly informative as they may point to
genes that are activated or silenced by other means, such as
deletions of APAF1 and FBXW7. APAF1 maps to 12q22-23, a
region associated with common LOH in GBM (Watanabe et al.,
2003). APAF1 is a critical component of the apoptosome and
caspase-9 activation (Li et al., 1997b). Inactivation of this path-
way has been implicated in GBM as highlighted by recent work
showing near universal upregulation of Bcl2L12, a regulator of
apoptosis downstream of APAF1 (Stegh et al., 2007). FBXW7
is a haplo-insufficient tumor suppressor gene (Mao et al., 2004)
recently shown to be frequently inactivated in T cell lymphomas
by mutation or deletion (Malyukova et al., 2007; Maser et al.,
2007). As it encodes an F-box protein that is part of the ubiquitin
protein ligase complex, FBXW7 has many known glioma-
relevant client proteins including cyclin E, c-Myc, Aurora-A,
Notch, and c-Jun. In addition to a large body of literature impli-
cating the Myc network in GBM (Bredel et al., 2005), as well as
presence of MYC amplification in GBM (Table 1, no. 6), FBXW7
expression itself has recently been correlated with GBM patient
survival (Hagedorn et al., 2007) although a direct pathogenetic
role in GBM has not been established. Interestingly, FBXW7
and APAF1 do not exhibit copy number-driven expression
profiles among GBM tumors, consistent with their infrequent
occurrence, thus pointing to alternative more common mecha-
nisms for their inactivation in GBM. Accordingly, APAF1 has
been known to be inactivated by methylation (Soengas et al.,
2001) and FBXW7 by inactivating point mutations (Moberg
et al., 2001). These findings of infrequent but focal deletionCancer Cell 13, 355–364, April 2008 ª2008 Elsevier Inc. 361
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should motivate direct examination of the mechanism and roles
of APAF1 and FBXW7 inactivation in GBM.
The GBM oncogenome is highly complex and harbors numer-
ous CNAs, many of which presumably target yet-to-be-discov-
ered GBM cancer genes. We have demonstrated here that
GTS can address one critical need in the development of a
functional map of GBM genetic targets: namely, to prioritize
those genomic alterations that are likely to be of importance
from among those that are more likely to be bystanders of the
cancer process. In particular, GTS has prioritized 100 top-rank-
ing ROIs, encompassing a total of only 138 resident genes
representing a limited list of candidates for downstream func-
tional validation. Among these 138 candidates are 42 that
exhibited significant copy number-concordant expression pat-
terns, including 10 validated GBM genes, pointing to high prob-
ability of biological relevance for the remaining 32 GW-significant
candidates residing within these ROIs. On the other hand, as
exemplified by APAF1 and FBXW7, non-GW-significant resi-
dents may also represent targets of rare genomic events that
are more commonly dysregulated by other mechanisms, render-
ing them similarly productive entry points for identification of
mutations or epigenetic alterations. Downstream functional
validation of these high probability candidates should yield novel
GBM genes and potential targets for therapeutic intervention.
EXPERIMENTAL PROCEDURES
Cell Lines and Tumors
Frozen tumor specimens (Table S1A) were obtained from the Memorial Sloan-
Kettering Cancer Center tumor bank. All tumor specimens were collected after
obtaining written informed consent preoperatively. This study was approved
by the Institutional Review Board of the hospital. Each tumor was confirmed
histopathologically to be grade IV glioblastoma. Glioma cell lines (Table S1B)
were propagated in RPMI-1640 medium supplemented with 10% FBS and
penicillin/streptomycin/amphotericin B. Normal human astrocytes were
obtained from ScienCell and Cambrex and propagated in astrocyte medium
(ScienCell). Murine astrocytes were propagated in DMEM supplemented
with 10% FBS and penicillin/streptomycin/amphotericin B. DNA from tumors
and cell lines was isolated with DNeasy (QIAGEN). RNA was isolated with Trizol
(Invitrogen), digested with DNase (Promega), and purified with RNeasy
(QIAGEN). siRNAs were purchased from Dharmacon and transfected using
Lipofectamine 2000 (Invitrogen). Normal human brain RNA was purchased
from Ambion.
Proliferation and Tumorigenicity Assays
Soft agar assays were performed in duplicate or triplicate in 6-well plates. 5000
cells per well were seeded in regular medium containing 0.4% low-melting
agarose on bottom agar containing 1% low-melting agarose in regular
medium. After 14 days, colonies were stained with Iodonitrotetrazoliumchlor-
ide (Sigma) and counted. For bromodeoxyuridine (BrdU) labeling, cells were
incubated with 10 mM BrdU (Sigma) in regular medium for 30 min. Cells were
then ethanol-fixed, RNase-digested, and incubated with anti-BrdU (DAKO),
followed by a FITC-labeled secondary antibody (DAKO) counterstained with
propidium iodide and analyzed by flow cytometry. For in vivo tumorigenicity
assays, 106 genetically engineered astrocytes comixed with matrigel (Sigma)
were transplanted subcutaneously into flanks of Ncr nude mice (Taconic)
and followed for tumor development. Tumor size was measured by caliper
by the same operator over time. At termination of the experiment, tumors
were harvested and processed for pathological and molecular analyses. All
animal experiments were approved by Harvard’s Institutional Animal Care
and Use Committee (IACUC). Statistical analysis was performed with a
Student’s t test.362 Cancer Cell 13, 355–364, April 2008 ª2008 Elsevier Inc.Expression Analysis
Protein (10–30 mg) was resolved on 4%–12% Bis-Tris gradient gels (Invitro-
gen), transferred to a PVDF membrane (Perkin Elmer), and incubated with
antibodies against p18INK4C (mouse monoclonal antibody, Cell Signaling;
rabbit polyclonal antibody, LabVision), tubulin (Sigma), vinculin (Santa Cruz),
and Flag epitope (Sigma). Quantitative PCR was performed on an Mx3000P
cycler (Stratagene) using QuantiTect SYBR green (QIAGEN). Primers were
obtained from SuperArray. Reactions were performed as triplicates or quadru-
ples for both test and control primers. Relative expression was calculated with
the DDCt method. Reverse transcription was performed with Superscript II
(Invitrogen) and oligo-dT priming. Immunoprecipitation was carried out using
standard techniques. One milligram of cell lysate was incubated with 2 mg of
CDK6 antibody (Santa Cruz) overnight.
Retroviral Constructs
INK4A and INK4C cDNAs were PCR-amplified from pCMV-p18 (Dr. Y. Xiong)
and pFlag-p16 (Dr. C. Geisen) and cloned into pBabe-puro3 as both untagged
and as Flag fusions. INK4C point mutations were introduced using
QuikChange II (Stratagene). Three shRNA sequences were annealed (se-
quences available upon request) and cloned into pSuperRetroPuro (Oligoen-
gine). Retrovirus was produced in Phoenix A cells, and target cells were
infected at 48 hr and 72 hr past transfection in the presence of 5 mg/ml
polybrene (Sigma). Infected cells were selected with 2.5 mg/ml puromycin for
4 days before being assayed. Lentiviral shRNA constructs targeting GFP
and p18INK4C were obtained through the RNAi Consortium (TRC). Sequences
are available from their website.
Resequencing
GBM cell line DNAs were sequenced as previously described (Davies et al.,
2005) by direct sequencing of each exon with intronic flanking sequences
utilizing ABI big dye chemistry on ABI3730 machines. Each variant was
confirmed in three independent sequencing assays. Primer sequences are
available upon request.
Array-CGH
Genomic DNA was processed, labeled, and hybridized onto Agilent’s 60-mer
array-CGH microarrays with 44K or 244K density (for performance compari-
son, see (Greshock et al., 2007) according to manufacturer’s protocol.
Processing of array-CGH data to generate a segmented profile by circular
binary segmentation (CBS) (Lai et al., 2005; Venkatraman and Olshen, 2007)
was as detailed elsewhere (Aguirre et al., 2004). Complete profiles are depos-
ited on the GEO website under super-series accession no. GSE9200 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE9200).
Genome Topography Scanning
GTS is performed in two stages, starting with array-CGH data which has been
smoothed by CBS: (1) calculation of ARI and AFI for each aCGH probe position
in the genome, followed by (2) identification of local peaks in the combined
GTS scores (ARI*AFI). Separate ARI and AFI are calculated for gain and loss.
ARI is computed for each probe position as the mean of CBS-smoothed
log2 ratios across all samples showing chromosomal gain, and then likewise
for all samples showing loss. A focality-weighted ARI (fwARI) is calculated
for gain and loss similarly to ARI, but after weighting the smoothed log2 ratio
at each probe position by the number of genetic elements (genes, microRNAs,
etc.) spanned by the CNA event, accounting for linkage of CNA across multiple
CBS segments (see Supplemental Experimental Procedures). AFI is the ratio of
fwARI/ARI. To identify focal CNA events, regions of interest (ROIs) are then
defined by bounding local peaks in the combined GTS scores (ARI*AFI, equiv-
alent to fwARI, see Supplemental Experimental Procedures). In this analysis of
GBM data set, log2 ratio was used directly in the calculation of ARI and equal
weighting was applied to each genetic element (RefSeq gene list) for the AFI
score. Transformation of copy number and differential weighting of genetic
elements may be utilized depending on the application. GTS algorithm is avail-
able as an R package at http://cbio.mskcc.org/brennan and is in the process
of being submitted to BioConductor.
Cancer Cell
INK4 Feedback Circuit in GlioblastomaExpression Profiling and Gene Weight Significance Calculation
RNA expression profiling was performed at the Dana-Farber Microarray Core
facility using the U133Plus2.0 chip (Affymetrix). Gene weight (GW) was calcu-
lated as previously described (Aguirre et al., 2004; Carrasco et al., 2006;
Hyman et al., 2002). Briefly, for each gene probe set, GW of expression values
for test set ‘‘T’’ compared to reference set ‘‘R’’ is calculated by:
GWTvs:R =
T  R
sT + sR
where test and reference sets are defined by presence or absence, respec-
tively, of CNA in the chromosomal region including the gene. Chromosomal
amplifications are tested separately from deletions. Significance was deter-
mined by permuting sample labels for expression data (1000 permutations,
p value % 0.05). Genes with GW significance are considered exhibiting
‘‘copy number concordant expression.’’
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was carried out using the EZ ChIP kit
per manufacturer’s protocol (Upstate). Briefly, genomic DNA from 5 3 106
normal human astrocytes was formaldehyde crosslinked and sonicated in
300 ml of lysis buffer until the average DNA fragment length was 600 bp.
One-hundred microliters of lysate, diluted 10-fold in ChIP dilution buffer, was
used per IP reaction. Antibodies used were anti-E2F1 (Santa Cruz, sc-193),
anti-RB (Santa Cruz, sc-50), and rabbit control IgG (NeoMarkers,
NC-100-P). INK4C and ACTNB promoter fragments were amplified as
described (Blais et al., 2002).
ACCESSION NUMBERS
Complete profiles are deposited on the GEO website under super series
accession no. GSE9200 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE9200).
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures,
Seven Supplemental Figures, and Six Supplemental Tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/4/355/
DC1/.
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